Kestra Medical Technologies (NASDAQ:KMTS - Free Report) had its price objective reduced by The Goldman Sachs Group from $24.00 to $23.00 in a report released on Wednesday morning,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the stock.
A number of other equities analysts have also recently commented on KMTS. Bank of America started coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They set a "buy" rating and a $30.00 price target for the company. Piper Sandler assumed coverage on Kestra Medical Technologies in a research note on Monday, March 31st. They set an "overweight" rating and a $27.00 target price on the stock. Wells Fargo & Company started coverage on Kestra Medical Technologies in a research note on Monday, March 31st. They set an "overweight" rating and a $28.00 price target for the company. Wolfe Research initiated coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They issued an "outperform" rating and a $29.00 price objective on the stock. Finally, Stifel Nicolaus began coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They set a "buy" rating and a $28.00 target price for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $27.50.
View Our Latest Report on Kestra Medical Technologies
Kestra Medical Technologies Stock Down 3.9 %
Shares of NASDAQ:KMTS traded down $0.96 during trading on Wednesday, reaching $23.54. The company's stock had a trading volume of 189,415 shares, compared to its average volume of 264,607. Kestra Medical Technologies has a 12 month low of $20.00 and a 12 month high of $26.15.
Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last released its quarterly earnings results on Monday, April 14th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.61). During the same quarter in the prior year, the firm posted ($1.18) earnings per share.
Kestra Medical Technologies Company Profile
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Featured Stories
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
